FY2026 EPS Forecast for Avanos Medical Decreased by Analyst

Avanos Medical, Inc. (NYSE:AVNS) – Stock analysts at Zacks Research dropped their FY2026 earnings per share (EPS) estimates for Avanos Medical in a research report issued to clients and investors on Tuesday, December 31st. Zacks Research analyst R. Department now forecasts that the company will earn $1.99 per share for the year, down from their prior forecast of $2.00. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share.

Separately, StockNews.com cut shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Performance

Shares of AVNS stock opened at $15.83 on Friday. Avanos Medical has a one year low of $15.51 and a one year high of $25.36. The company’s 50-day moving average is $18.46 and its 200 day moving average is $21.06. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The company has a market capitalization of $727.50 million, a price-to-earnings ratio of 46.56 and a beta of 0.95.

Institutional Investors Weigh In On Avanos Medical

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Avanos Medical by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock worth $25,337,000 after acquiring an additional 16,065 shares in the last quarter. Foundry Partners LLC boosted its position in shares of Avanos Medical by 1.1% during the third quarter. Foundry Partners LLC now owns 163,030 shares of the company’s stock worth $3,918,000 after buying an additional 1,800 shares during the period. AQR Capital Management LLC increased its stake in Avanos Medical by 21.0% during the 2nd quarter. AQR Capital Management LLC now owns 146,983 shares of the company’s stock worth $2,875,000 after buying an additional 25,467 shares during the period. FMR LLC grew its position in shares of Avanos Medical by 34.6% during the third quarter. FMR LLC now owns 133,844 shares of the company’s stock worth $3,216,000 after buying an additional 34,421 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Avanos Medical by 12.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 108,470 shares of the company’s stock valued at $2,607,000 after buying an additional 11,613 shares in the last quarter. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.